The purpose of this study is to evaluate the change in terminal hair count at 16 and 26 weeks compared to baseline measurements.
This is randomized, double-blind, control device clinical study across 3 sites, evaluating changes in terminal hair-count in the evaluation zone having evidence of androgenetic alopecia (miniaturized hair). The trial will involve approximately 75 male subjects who have been diagnosed with androgenetic alopecia, who are between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of Norwood-Hamilton IIa to V, have active hair loss within the last 12 months. Subjects will use the device on three non-consecutive days a week as directed per device for 26 weeks treatment duration. Safety analysis will be assessed based on the reports of adverse events during study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
79
Device application 3 times week (non-consecutive days), for 26 weeks
Device is used 3 times a week on non-consecutive days
Abe Marcadis, M.D.
West Palm Beach, Florida, United States
David Goldberg, M.D.
Hackensack, New Jersey, United States
Zoe Draelos, M.D.
High Point, North Carolina, United States
Changes in Terminal Hair Count at 16 and 26 Weeks Compared to Baseline in Men Diagnosed With Androgenetic Alopecia
The primary analysis of effectiveness was an analysis of covariance, which separately modeled terminal hair count at Week 16 and Week 26 as a function of treatment group (HairMax LaserComb 2009 9 Beam vs.control), study center, age (as a continuous variable), and Fitzpatrick Skin Type classification (as a categorical variable with four levels). The active group was compared to the control device using least squares means with a two-sided test at the 5% level of significance.
Time frame: baseline, 16 and 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.